tbc-11251 has been researched along with Chemical and Drug Induced Liver Injury, Chronic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cross, DM; Derzi, M; Horsley, E; Owen, K; Stavros, FL | 1 |
1 other study(ies) available for tbc-11251 and Chemical and Drug Induced Liver Injury, Chronic
Article | Year |
---|---|
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (ThelinĀ®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Topics: Alkaline Phosphatase; Animals; Antihypertensive Agents; Blood Coagulation; Carcinogenicity Tests; Carcinogens; Chemical and Drug Induced Liver Injury, Chronic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Erythrocyte Indices; Female; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Liver; Liver Function Tests; Male; Mice; Mice, Inbred Strains; Organ Size; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Thiophenes | 2012 |